Telehealth ketamine therapy provider Mindbloom is facing a wrongful-death lawsuit after a 27-year-old male patient died from ketamine toxicity in October 2023, allegedly while under Mindbloom’s at-home treatment program. The lawsuit contends that the company failed to properly screen the patient—who had a documented history of substance-use disorder and hypertension—and did not follow through with required follow-up monitoring once he missed mandated check-ins. The patient’s family argues that, despite Mindbloom’s public claim that none of its ~60,000 patients had ever overdosed, this case marks a tragic exception. Mindbloom, while expressing sympathy for the death, denies negligence and asserts its care protocols are supported by peer-reviewed research and numerous prior treatments.